Seattle psilocybin by the numbers

The short answer

An estimated 4.55% of Washington residents aged 12 and older used any hallucinogen in the past year (2023 to 2024), above the U.S. figure of 3.36%.¹ Nationally, 2.2% used psilocybin itself in 2025.² In fall 2025, 3.3% of Washington 12th graders said they had ever used it.³ From April to June 2026, at least 43.0% of clients at Oregon's licensed service centers gave another U.S. state as home; Oregon doesn't count Washington residents separately.⁹ And ClinicalTrials.gov lists 10 psilocybin trials and 1 psilocin-analog trial with a Washington site.¹³ The Washington Poison Center publishes no psilocybin count.⁵

The figures

Each figure has its period, denominator and primary source. "Past year" means at least once in the prior 12 months; "lifetime" or "ever" means at least once. Each row has an anchor for linking, such as the Oregon out-of-state share.

How many people use psilocybin

• 4.55%

  Share of Washington residents aged 12 and older who used any hallucinogen in the past year.

  Denominator: Washington's civilian, noninstitutionalized population aged 12+ (95% interval 3.60% to 5.73%); the U.S. figure is 3.36%, a statistically significant difference (p = 0.012). Hallucinogens here are LSD, PCP, peyote, mescaline, psilocybin, MDMA, ketamine, DMT and Salvia combined, and the state tables have no psilocybin row.

  SAMHSA, NSDUH State Estimates, Table 11, 2023 to 2024 annual average

• 305,000

  Estimated number of Washington residents aged 12 and older who used any hallucinogen in the past year.

  A model estimate, not a head count (95% interval 242,000 to 385,000); about 58,000 were aged 18 to 25 and 237,000 were 26 or older. All hallucinogens, not psilocybin alone.

  SAMHSA, NSDUH State Estimates, Table 11 (numbers), 2023 to 2024 annual average

• 7.76%

  Share of Washington young adults aged 18 to 25 who used any hallucinogen in the past year.

  95% interval 5.73% to 10.43%; the U.S. figure is 6.73%, and the difference is not statistically significant (p = 0.380). All hallucinogens, not psilocybin alone.

  SAMHSA, NSDUH State Estimates, Table 11, 2023 to 2024 annual average

• 4.39%

  Share of Washington adults aged 26 and older who used any hallucinogen in the past year.

  95% interval 3.39% to 5.67%; the U.S. figure is 3.06%, a statistically significant difference (p = 0.006). All hallucinogens, not psilocybin alone.

  SAMHSA, NSDUH State Estimates, Table 11, 2023 to 2024 annual average

• 3.36%

  Share of all U.S. residents aged 12 and older who used any hallucinogen in the past year, the comparison for the Washington rows.

  A direct survey estimate (95% confidence interval 3.19% to 3.54%), while the state figures come from a statistical model. Same definition of hallucinogens as the Washington rows.

  SAMHSA, NSDUH State Estimates, Table 11, 2023 to 2024 annual average

• 7th of 51

  Washington's place among the 50 states and the District of Columbia on past-year hallucinogen use at ages 12 and older.

  Colorado (7.29%) ranks 3rd and Oregon (6.62%) 4th, and Washington's estimate is significantly lower than both (p = 0.002 and p = 0.019). A rank on point estimates is not a significance test.

  SAMHSA, NSDUH State Estimates, Table 11 and p value Table 11.1, 2023 to 2024 annual average

• 4.22%

  Share of Washington residents aged 12 and older who used any hallucinogen in the past year, in the previous two-year estimate.

  Ages 18 to 25: 9.39%; ages 26 and older: 3.74%; U.S. ages 12 and older: 3.06%. This pair shares 2023 interviews with the 2023 to 2024 pair, so the change between them should not be read as a trend.

  SAMHSA, NSDUH State Estimates 2022 to 2023, Table 11, 2022 to 2023 annual average

• 2.2%

  Share of U.S. residents aged 12 and older who used psilocybin in the past year, about 6.5 million people.

  Down from 2.7% (about 7.9 million) in 2024, a decline SAMHSA marks as significant at the .01 level. National only: no state or city psilocybin estimate is published.

  SAMHSA, 2025 NSDUH Detailed Tables 1.119A and 1.119B, 2025

• 4.5%

  Share of U.S. young adults aged 18 to 25 who used psilocybin in the past year, about 1.6 million people.

  Down from 5.4% in 2024 (significant at the .05 level); in 2025 the figure was 2.0% for adults 26 and older and 1.0% for ages 12 to 17. National only.

  SAMHSA, 2025 NSDUH Detailed Tables 1.119A and 1.119B, 2025

• 11.8%

  Share of U.S. residents aged 12 and older who have used psilocybin at least once in their lives, about 34.2 million people.

  Lifetime use, not recent use; the 2024 figure was 12.3%. National only.

  SAMHSA, 2025 NSDUH Detailed Tables 1.118A and 1.118B, 2025

Young people

• 1.86%

  Share of Washington adolescents aged 12 to 17 who used any hallucinogen in the past year.

  95% interval 1.26% to 2.75%; the U.S. figure is 1.53%, and the difference is not statistically significant (p = 0.317). All hallucinogens, not psilocybin alone.

  SAMHSA, NSDUH State Estimates, Table 11, 2023 to 2024 annual average

• 3.3%

  Share of Washington 12th graders who said they had ever used psilocybin (or magic mushrooms, shrooms).

  Margin plus or minus 1.2 points, from a statewide sample of 28,683 students in 165 schools. The report found 12th grade males more likely than females to report it.

  Healthy Youth Survey 2025 Analytic Report, pp. 193 and 194, Fall 2025 (surveyed August to October 2025)

• 1.5%

  Share of Washington 10th graders who said they had ever used psilocybin.

  Margin plus or minus 0.5 points. 2025 was the first year the survey asked about lifetime psilocybin use, so there is no earlier lifetime figure to compare.

  Healthy Youth Survey 2025 Analytic Report, pp. 131 and 194, Fall 2025 (surveyed August to October 2025)

• 0.5%

  Share of Washington 8th graders who said they had ever used psilocybin.

  Margin plus or minus 0.2 points. The report says each higher grade was more likely to report lifetime use.

  Healthy Youth Survey 2025 Analytic Report, pp. 193 and 194, Fall 2025 (surveyed August to October 2025)

• 1.9%

  Share of Washington 12th graders who said they had used psilocybin to get high in the past 30 days.

  Margin plus or minus 0.7 points; 10th grade was 1.3% and 8th grade 1.0%. This 2023 question was the survey's first item on psilocybin alone (a 2002 item grouped magic mushrooms with LSD and PCP as psychedelics) and was not repeated in 2025, so it can't be set against the 2025 lifetime figures as a trend.

  Healthy Youth Survey 2023 Analytic Report, p. 107 and question 49, Fall 2023

Poisonings and emergencies

• 65,473

  People the Washington Poison Center helped in 2025, for any substance.

  58,646 had a potential poisoning and 6,287 had a question, across 129,422 calls including follow-ups; more than one-third of patients were aged 5 or younger. The report gives no figure for mushrooms or psilocybin.

  Washington Poison Center, 2025 Annual Report, 2025

• 2

  People in Washington the Poison Center identified as hospitalized after eating Diamond Shruumz chocolate, cones or gummies.

  Nationally, at least 69 people in 28 states had become sick and 36 had been hospitalized as of July 15, 2024. A product cluster, not a count of psilocybin cases.

  Washington Poison Center advisory, As of July 18, 2024

Legal access nearby

• 1,220

  Clients served at Oregon's licensed psilocybin service centers in the second quarter of 2026.

  The latest quarter published as of November 2, 2026; 291 clients opted out of data collection that quarter. The services are legal only in Oregon's licensed settings.

  Oregon Health Authority, data file 2026 Q2, April 1 to June 30, 2026

• 43.0%

  Share of Oregon psilocybin clients in the second quarter of 2026 who gave a U.S. state other than Oregon as home (525 of 1,220).

  Oregon does not report Washington State residents separately, and the file's column headed Washington is Washington County, Oregon. Residence answers are voluntary (291 clients opted out of data collection and 51 left the question blank), so 525 is a minimum. By quarter since early 2025 the share ran 24.5%, 25.5%, 36.9%, 33.4%, 37.9% and 43.0% of clients served (earlier quarters from OHA's data archive).

  Oregon Health Authority, data file 2026 Q2, April 1 to June 30, 2026

• 5,935

  Clients served at Oregon's licensed psilocybin service centers in 2025.

  The sum of four quarterly counts, so a person served in more than one quarter may be counted more than once. Centers held 4,628 individual and 747 group sessions.

  Oregon Health Authority, 2025 Year-End Data Summary, Calendar 2025

• 1,753

  Oregon psilocybin clients in 2025 who gave another U.S. state as home.

  29.5% of the 5,935 clients served, or 55.2% of the 3,174 with a listed answer; 183 gave a home outside the U.S. and 446 did not answer. Washington State is not reported separately, and the summary's line labeled Washington is Washington County, Oregon.

  Oregon Health Authority, 2025 Year-End Data Summary, Calendar 2025

• Over 50,000

  Psilocybin products sold by Oregon's licensed service centers to clients for administration sessions since the program began.

  A count of products, not people: OHA says the total may include secondary doses. In 2025 alone, centers sold 18,877 products.

  Oregon Health Authority, psilocybin budget overview, October 2026, As of October 1, 2026

• 47

  Approved healing center licenses in Colorado's natural medicine program (12 standard, 35 micro).

  Up from 34 (9 standard, 25 micro) as of January 30, 2026, in the Division's annual report. A count of approved licenses; the page does not say how many centers are operating.

  Colorado Natural Medicine Division, approved licenses, As of October 30, 2026

• 109

  Participants served at Colorado's licensed healing centers from August to December 2025, as reported voluntarily by the centers.

  Preliminary data from centers in Boulder, Douglas, Eagle, Jefferson and Pitkin counties; October was the busiest month, with 40. The report gives no share of participants from other states.

  Colorado Department of Revenue, Annual Natural Medicine Implementation Report, February 2, 2026, August to December 2025

Research in Washington

• $1,464,000

  State money provided to the University of Washington solely to carry out the 2023 psilocybin law, 2SSB 5263.

  From the workforce education investment account. The law (chapter 364, Laws of 2023) set up a psilocybin therapy services pilot in UW's psychiatry department, subject to appropriation, to start no later than January 1, 2025.

  Chapter 475, Laws of 2023, Sec. 606(85), 2023 to 2025 state budget

• $730,000

  State money provided to the University of Washington solely to carry out chapter 364, Laws of 2023 (psilocybin).

  From the workforce education investment account, in the 2025 to 2027 operating budget; about half the 2023 to 2025 amount. The governor's partial veto of that budget section did not touch this subsection.

  Chapter 424, Laws of 2025, Sec. 606(50), 2025 to 2027 state budget

• 40

  Planned enrollment of PsiloStudy, the UW trial of psilocybin for veterans and first responders with PTSD and alcohol use disorder.

  A registry estimate, not an enrolled count; the record lists Washington State Legislation as a collaborator and the status as active, not recruiting. The number actually enrolled has not been published.

  ClinicalTrials.gov, NCT06853912, Registry record updated August 13, 2026

• 11

  Psilocybin studies on ClinicalTrials.gov with at least one site in Washington State.

  5 active and not recruiting, 4 completed and 2 recruiting; 8 list a Seattle site. That is about 5.7% of the 192 psilocybin studies with a U.S. site. These are records that match the search term psilocybin: one of the 11 (CYB003) tests a deuterated psilocin analog rather than psilocybin itself.

  ClinicalTrials.gov registry search, As of November 2, 2026

• 29

  PubMed records that match psilocybin and list a University of Washington affiliation.

  22 of the 29 are about psilocybin; the other 7, mostly brain imaging consortium papers, don't mention it in the title, abstract or subject terms. 8 carry a 2026 publication date, a partial year.

  PubMed search, All years, as of November 2, 2026

Enforcement

• 1,571

  Drug and narcotic violation offenses (NIBRS code 35A) recorded by Seattle Police in 2025, for all substances.

  By year: 371 in 2021, 680 in 2022, 634 in 2023, 1,079 in 2024, and 1,398 in 2026 through November 1. Offenses, not arrests or charges, and the data have no substance field, so psilocybin can't be separated.

  City of Seattle open data, SPD Crime Data, 2025, by offense date

Distance

• 174 mi

  Driving distance from downtown Seattle to downtown Portland, used here as the reference point for Oregon's licensed service centers.

  280 km, about 3.4 hours with no traffic. Individual center addresses were not used, so the distance to a given center will differ.

  OSRM route service, Computed November 2, 2026

• 1,168 mi

  Driving distance from downtown Seattle to Montrose, the nearest town by road with a healing center in Colorado's directory.

  1,879 km, about 21 hours with no traffic; downtown Denver is 1,304 miles. The directory is submitted by the centers themselves, and a town center point was used.

  OSRM route service, Computed November 2, 2026

What the adult survey can and can't say about psilocybin

The National Survey on Drug Use and Health estimates state drug use by pooling two years of interviews and modeling small samples, so Washington's 4.55% carries an interval of 3.60% to 5.73%.¹ Its "hallucinogens" combine LSD, PCP, peyote, mescaline, psilocybin, MDMA, ketamine, DMT and Salvia, and the state tables have no psilocybin row.¹ Washington is significantly above the U.S. at ages 12 and older and 26 and older, not at 12 to 17 or 18 to 25, and significantly below Oregon and Colorado.¹

SAMHSA's separate psilocybin question is published for the nation only: 2.7% in 2024 and 2.2% in 2025, a significant drop.² Applying that share to Washington would be a guess, so we don't. As of November 2, 2026, the newest state release covered 2023 to 2024.¹

The youth survey's first psilocybin questions

Washington's Healthy Youth Survey first asked about psilocybin on its own in fall 2023 (its 2002 survey had grouped "magic mushroom" with LSD and PCP under psychedelics), as one choice in a question about substances used "to get high" in the past 30 days. It was checked by 1.0% of 8th graders, 1.3% of 10th graders and 1.9% of 12th graders.⁴ The 2025 survey asked instead whether students had used it "ever, even once": 0.5%, 1.5% and 3.3%.³

The 2025 report prints the 30-day figures in its 2023 column and marks 2025 as not asked, so they aren't 2025 results.³ Different years and questions mean no trend can be read across them. The report says each higher grade was more likely to report lifetime use, and 12th grade males more likely than females, and it lists psilocybin among substances whose reported use "remains low".³ These are statewide figures, not Seattle's.

Why there is no poison-center count

The Washington Poison Center doesn't publish its cases by substance. Its data page says all data requests go through a form, are filled at the center's discretion and carry fees set after review.⁵ Its 2025 annual report counts 65,473 people helped, with no line for mushrooms.⁶

The latest statewide mushroom figure we found is from 2015, when The Daily Herald (Everett) reported, citing the center, 279 calls that year through mid-November from people who ate a mushroom of any kind and had symptoms.⁷ In July 2024 the center linked two Washington hospitalizations to Diamond Shruumz chocolate, cones and gummies.⁸ No public figure shows whether psilocybin exposures have risen or fallen, and a missing number is not evidence of few cases. For a suspected mushroom poisoning, call Poison Control at 1-800-222-1222.

What Oregon and Colorado figures tell a Seattle reader

Downtown Portland is about 174 miles from Seattle by road.¹⁷ Oregon's services are legal only inside its licensed program, where psilocybin is bought and taken during a supervised session at a service center and can't be taken off site,¹⁸ and psilocybin remains a Schedule I substance under Washington law.¹⁶ Our visitors' entry covers Washington law.

Oregon's out-of-state share rose from 24.5% of clients served in early 2025 to 43.0% (525 of 1,220) from April to June 2026.⁹ Oregon doesn't separate Washington residents within those 525, and the data file's column headed "Washington" is Washington County, Oregon.⁹ Residence forms are voluntary (291 clients opted out of data collection that quarter and 51 left the question blank), so 525 is a minimum and 43.0% a floor.⁹ Oregon's 2025 total of 5,935 clients equals the sum of its four quarterly counts, so a person served in more than one quarter may be counted more than once.⁹¹⁰

Colorado had 47 approved healing center licenses as of October 30, 2026, and centers reported 109 participants from August to December 2025, with no out-of-state share.¹¹¹²

The gaps, and who could close them

Two gaps could be closed with existing data: the poison center's records can be filtered by substance, and SAMHSA already asks about psilocybin nationally.⁵² We found no published poll of Washington opinion on psilocybin. The trials are listed in our research register, and the 2023 pilot law is on the timeline.

How we compiled these figures

We worked from primary files (SAMHSA's state, p value and national tables, Oregon's quarterly data, both Healthy Youth Survey reports, the poison center's annual report and Washington's session laws) and from the ClinicalTrials.gov, PubMed, Seattle open data and OSRM routing services, all checked on November 2, 2026. An "offense" is one police record, not an arrest. We left out figures we couldn't trace to a primary record, such as a press count of Oregon service centers and a crime lab count of unclear geography. We also found that the youth survey's 30-day figures belong to 2023, not 2025.

The dataset is free to reuse under CC BY 4.0: credit this almanac, link to this page and cite each figure's primary source. To report an error, email almanac@magicmushroomsseattle.org with the figure's anchor and your source, or use the contact page; corrections follow our editorial standards.